SPY002 Updated Nov 4
The next hard catalyst for SPY002 is the SKYLINE Part B combination-therapy topline data expected in Q3 2027. Positive data would validate Spyre's combination strategy and could drive significant upside; negative data would undermine the entire platform thesis. The company also has SPY072 SKYWAY data and SKYLIGHT HS data as additional catalysts in late 2027/early 2028.
- SPY002 met its Phase 2 SKYLINE Part A primary endpoint with a 10.7-point RHI reduction (p<0.0001), plus 33% clinical remission and 42% endoscopic improvement at Week 12, which the company characterizes as among the highest reported in UC.
- Extended half-life (~75 days) enables potential quarterly or twice-annual subcutaneous maintenance dosing, a significant convenience advantage over first-generation competitors that require more frequent dosing.
- All three IBD monotherapies (SPY001, SPY002, SPY003) achieved positive proof-of-concept in SKYLINE Part A, validating the platform and enabling the combination strategy in Part B.
- Intense TL1A competition: Roche (RVT-3101), Teva/Sanofi (duvakitug, Phase 3), and Merck (tulisokibart, Phase 3) are all ahead or at similar stages with first-generation anti-TL1A antibodies, and duvakitug already has positive Phase 2b maintenance data.
- SPY072, a sibling anti-TL1A molecule, disappointed in rheumatoid arthritis (SKYWAY trial, August 2026), missing internal benchmarks and causing a stock decline, raising questions about the TL1A platform's breadth.
- SKYLINE Part B combination data is not expected until Q3 2027, leaving a long data-free period during which the stock is exposed to competitive readouts and market sentiment.